Study wrapper · #913
Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.
Editor's note
This is an expert-opinion consensus paper rather than new primary data, so it reflects panel judgment layered on existing evidence such as the SELECT trial. Semaglutide is discussed as a disease-modifying option associated with cardiovascular risk reduction largely independent of weight loss. Readers should note the guidance is Italy-specific in its care-model and reimbursement framing. Useful as context on how specialists are integrating semaglutide into secondary prevention.
Plain-language abstract
An Italian expert panel offers consensus guidance on using semaglutide in patients who have both cardiovascular disease and overweight or obesity, drawing on SELECT trial data. It also outlines practical barriers to wider use, such as reimbursement and clinical inertia.